"Genentech is an immensely diverse, challenging and motivating place to work. The company has an incredibly bright and talented group of individuals who bring a diverse set of talents and viewpoints to our collaborative, team-based organization. I get a great deal of personal satisfaction from working in this great environment and with such talented individuals in order to bring potentially life-altering and life-saving therapeutics to patients."
I joined Genentech in January 2003 as a Senior Scientist-Pathologist in the Department of Pathology in Research. After 5+ years as a Research Scientist-Pathologist, in May 2008 I transitioned to the role of a Toxicologic Scientist-Pathologist in the Department of Safety Assessment in Development Sciences in order to further develop myself as a drug development scientist. In November 2011, I was promoted to Principal Scientist-Pathologist in Safety Assessment.
In total, I have spent nearly 23 years in the biopharmaceutical industry working as both an experimental and toxicologic pathologist. During this time, I have gained experience and expertise in tissue based discovery research, development and evaluation of animal models, and both nonclinical and clinical drug development. I have authored over 60 peer-reviewed publications, including 1 book chapter, 6 review papers and 17 publications where I am sole, first or senior author. I am also a co-author on six patents.
I have been board-certified in veterinary pathology (DACVP) for 25 years and am a member of several pathology societies, including the American College of Veterinary Pathologists, the Society of Toxicologic Pathology and the American Society for Investigative Pathology. I am also on the Board of Directors for the CL Davis Foundation for the Advancement of Veterinary and Comparative Pathology, and served as the Foundation’s West Coast Program Director from 2001 through 2014.
Toxicol Pathol. 2012; 40(2): 272-87.
My areas of expertise and special interest are in both basic and translational research as well as in drug development in the areas of cutaneous disease and biology, and the biology, pathology and toxicology of the immune system. For both the cutaneous and immune systems, I am interested in both in vitro and in vivo models of cutaneous and immune system biology, disease, injury and toxicity, as well as in the pathology and toxicology of the skin and immune system, and in particular, the mucocutaneous immune system. I also have interest and expertise in the pathology of mice, particularly genetically engineered mice.